A small study suggests Mavenclad’s effectiveness in MS may be linked to how regulatory T-cells respond to treatment.
Teva Canada and Novartis Canada are collaborating to ensure continued access to Mayzent for people with active SPMS in Canada ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results